Half of patients remained progression-free without maintenance
Half of patients remained progression-free without maintenance
Partnership brings key medicines to eight markets
Company prepares seamless transition into phase 2a development
Nations commit US$240 million to CEPI’s 2027–2031 strategy
Grants support studies into restorative sleep and disease mechanisms
New option for patients with systemic lupus erythematosus
Deal strengthens company’s established medicines strategy
Regulator supports earlier multiple myeloma treatment option
Trial shows reduced ALS decline and BBB target engagement
Strategic deal to advance mature medicines globally
New format simplifies administration for clinicians
Collaboration supports first‑in‑human gene therapy trial preparation
Submission marks major milestone for novel excipient BLG
Trials suggest meaningful reductions in exacerbations
Phase 3 data supports combined vaccine technologies